Case-Based Roundtable

General Dermatology 

Eczema

Chronic Hand Eczema

Chronic Spontaneous Urticaria 

Alopecia

Aesthetics

Vitiligo

COVID-19

Actinic Keratosis 

Precision Medicine and Biologics

Rare Disease

Wound Care

Rosacea 

Emerging Therapies Plaque Psoriasis

Treatments for Plaque Psoriasis 

Psoriasis 

Psoriatic Arthritis 

Biologic Treatments for Moderate to Severe Atopic Dermatitis 

Atopic Dermatitis 

Melasma

NP and PA

Skin Cancer (Nonmelanoma)

Skin Cancer

Hidradenitis Suppurativa

Drug Watch

Pigmentary Disorders 

Acne 

Pediatric Dermatology

Practice Management 

Prurigo Nodularis

Buy-and-Bill

News

Media

Around the Practice

Between The Lines

Case-Based Peer Perspective

Clinical Case Collective

DermView

Expert Perspectives

Fellows Face Off

Frontline Forum

Medical World News

Patient Perspectives

Podcasts

Readout360

Recognize and Refer

Conferences

Conference Coverage

Conference Listing

Events

Publication

Dermatology Times

CME/CE

Resources

DermIQ

Interactive Tools

Job Board

Partner Perspectives

Perspectives in Dermatology

Polls

Spot Test

Editorial Advisory Board

Partners

Subscribe

and joined the MJH Life Sciences team in February 2023. She attended Kent State University and earned a Bachelor of Science degree in journalism with minors in public relations and creative writing. She enjoys making and listening to music, reading, and spending time with her cats, Astrid and Marceline.

Articles

This review of the latest dermatologic studies includes insights into skin improvement with injectable hyaluronic acid, burden of chronic spontaneous urticaria, and more.

Journal Digest: June 11, 2025

Catch up on dermatology news, highlights, and insights from the past 24 hours.

Daily Derm Times: June 10, 2025

Christopher Bunick, MD, PhD, is an associate professor of dermatology and physician-scientist at the Yale School of Medicine in New Haven, Connecticut, and 

At RAD 2025, Christopher Bunick, MD, PhD, presented data on amlitelimab and rocatinlimab, highlighting their potential to suppress cytokine signaling and more.

OX40/OX40L Inhibitors Offer Upstream Signaling Pathways in Atopic Dermatitis

Marie Bosslett is the assistant editor of 

 and joined the MJH Life Sciences team in October 2024. She attended Loyola University Maryland in Baltimore and earned a Bachelor of Arts in Communication with minors in marketing and writing. When she’s not writing, Marie enjoys going to concerts, reading on the beach, and spending time with friends and family.

Galderma unveils promising long-term data on nemolizumab for atopic dermatitis, showcasing significant skin improvement and quality of life enhancements.

Late Breaking Data: Long-Term Safety and Efficacy of Nemolizumab for AD

Dermatology Times connects dermatology professionals with key skin disorder coverage, therapeutic strategies, clinical trial updates, and expert insights.

About

Advertise

Contact Us

Do Not Sell My Information

Terms and Conditions

Privacy Policy

Dermatology Times - Dermatology News and Clinical Insights

Facebook

Linkedin

Topics

Acne

Pigmentary Disorders

Practice Management

Psoriasis

Psoriatic Arthritis

Rosacea

Chapter 1

OX40 Ligand (OX40L) Pathway Resource Center

Highlighting unmet needs in atopic dermatitis (AD) and understanding disease pathogenesis

Chalk Talk - Understanding the Role of the OX40L Pathway in AD

MAT-US-2410187 v2.0 - P Expiration Date: 10/22/2025